Targeting Leukemia causing oncogene E2a-Pbx1 with synthetic molecules

描述（由申请人提供）：生物体中的所有细胞，除了少数例外，都具有相同的基因组，但它们专门产生具有不同形态和功能的组织。这种多样性是由于在发育和细胞分化过程中以程序化方式表达的基因组的差异而产生的。最近人类基因组的解码，加上全基因组表达谱，正在澄清特定基因表达模式和细胞命运之间的关系。基因表达模式是由一系列转录调控因子控制的。在许多类型的癌症中，通常是转录调节因子发生故障，产生基因表达的异常模式，这是疾病的核心。在这种情况下，它是至关重要的，以确定致癌转录调节因子的调控目标，并开发合成的分子，可以控制他们的表达。理想地，此类合成分子或人工转录因子（ATF）将被工程化以在调控网络内正向或负向调控靶基因。这些分子将成为功能基因组学的有力工具，也可以解开控制细胞命运的特定基因的关键转录事件。从长远来看，ATFs作为化疗药物具有重要的潜力。该提案的一个主要目标是确定两个致癌转录因子E2 a-Pbx 1和HoxA 9的DNA调控位点。E2 a-Pbx 1与25%的诊断的儿童前B细胞白血病（B-ALL）的发病有关，HoxA 9的失调与急性髓性白血病（AML）的病因有关。这两种蛋白质的全基因组DNA调控位点的鉴定将作为理解控制这些癌症发病的基因调控网络的基础。当前提案的第二个主要目标是开发靶向和抑制人类致癌基因E2 a-Pbx 1的合成分子。这一努力建立在我们成功靶向果蝇同源转录因子和上调真核基因表达与合理设计的人工转录因子。拟议的研究将提供框架，以开发目标和调节其他致癌转录因子的转录和致癌特性的ATF。因此，我们将开发一种通用的方法来构建复杂的ATF，这些ATF与内源性转录因子一起调节基因对细胞信号的反应。总之，我们的工作将产生强大的工具，可用于研究转录调控的棘手机制特征，剖析全基因组转录网络，作为触发所需转录级联反应的指南，并控制细胞和生物体的命运。 公共卫生相关性：该基金的重点是通过利用基因组和化学策略靶向致癌蛋白E2 a-Pbx 1来理解和控制控制白血病发病的基因网络。我们的小分子抑制剂的模块化设计原理允许巨大的宽度，并广泛适用于与许多不同癌症有关的各种转录调节因子。此外，我们发明的基因组定位和表达研究以及同源位点鉴定平台在阐明基因网络的性质方面具有直接效用，所述基因网络由于广泛的转录调节因子的误调节而导致特定形式的癌症。

DESCRIPTION (provided by applicant): All cells in an organism, with a few exceptions, bear the same genome, yet they specialize to give rise to tissues with diverse morphology and function. This diversity arises due to the differences in sets of genes that are expressed in a programmed manner during development and cellular differentiation. The recent decoding of the human genome, coupled with genome-wide expression profiling, is clarifying the relationship between specific gene expression patterns and cell fate. Gene expression patterns are controlled by a host of transcription regulatory factors. In many types of cancers it is often malfunctioning transcriptional regulators that produce aberrant patterns of gene expression that are at the heart of the ailment. In this context, it is critical to identify regulatory targets of oncogenic transcriptional regulators and develop synthetic molecules that can control their expression. Ideally, such synthetic molecules or artificial transcription factors (ATFs) would be engineered to positively or negatively regulate targeted genes within regulatory networks. Such molecules would serve as powerful tools for functional genomics as well as for unraveling key transcriptional events at specific genes that govern cell fate. In the long term, ATFs have significant potential as chemotherapeutic agents. A major goal of this proposal is to define the DNA regulatory sites of two oncogenic transcription factors, E2a- Pbx1 and HoxA9. E2a-Pbx1 is implicated in the onset of 25% of all diagnosed pediatric pre B-cell leukemias (B-ALL) and the misregulation of HoxA9 is linked to the etiology of Acute Myeloid Leukemia (AML). The identification of genome-wide DNA regulatory sites of the two proteins will serve as the basis for understanding the gene regulatory networks that govern the onset of these cancers. The second major goal of the current proposal is to develop synthetic molecules to target and inactivate the human oncogene E2a-Pbx1. This effort builds on our success in targeting homologous transcription factors from Drosophila and the up-regulation of eukaryotic gene expression with rationally designed artificial transcription factors. The proposed studies will provide the framework to develop ATFs that target and regulate the transcriptional and oncogenic properties of other oncogenic transcription factors. We will thus develop a general approach to building sophisticated ATFs that act in concert with endogenous transcription factors to regulate genes in response to cellular signals. Together, our work will generate powerful tools that can be used to study intractable mechanistic features of transcriptional regulation, dissect genome-wide transcriptional networks, serve as guides to trigger desired transcriptional cascades and control the fate of cells and organisms. PUBLIC HEALTH RELEVANCE: This grant is focused on understanding and controlling the gene networks that govern the onset of leukemia by utilizing genomic and chemical strategies to target the oncogenic protein E2a-Pbx1. The modular design principle of our small molecule inhibitors permits enormous breadth and are broadly applicable to a variety of transcriptional regulators that have been implicated in many different cancers. In addition, the genome location and expression studies as well as the cognate site identification platform that we invented have direct utility in elucidating the nature of gene networks that cause specific forms of cancer due to misregulation of a broad swath of transcription regulators.